Who is sponsoring NCT06874933?

NCT06874933 is sponsored by First Affiliated Hospital of Zhejiang University.

What condition does NCT06874933 study?

NCT06874933 studies HR+/HER2- Breast Cancer.

Is NCT06874933 still recruiting?

NCT06874933 is currently recruiting now. Last updated 12 August 2025.

Last reviewed 2025-08-12 · How we verify

NCT06874933

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neoadjuvant Chemotherapy in Combination With Anlotinib and Benmelstobart for HR+/HER2- Breast Cancer (NEOTORCH-BREAST03)

Recruiting now Phase 2 Last updated 12 August 2025

What this trial tests

Phase 2 trial testing Neoadjuvant Chemotherapy in Combination with Anlotinib and Benmelstobart in HR+/HER2- Breast Cancer in 35 participants. Currently enrolling.

Timeline

4 May 2025

Primary endpoint
1 April 2027

1 April 2030

Quick facts

Lead sponsor	First Affiliated Hospital of Zhejiang University
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	35
Start date	4 May 2025
Primary completion	1 April 2027
Estimated completion	1 April 2030
Sites	3 locations across China

Drugs / interventions tested

Neoadjuvant Chemotherapy in Combination with Anlotinib and Benmelstobart — full drug profile →

Conditions studied

HR+/HER2- Breast Cancer — all drugs for HR+/HER2- Breast Cancer →

Sponsor

First Affiliated Hospital of Zhejiang University

Who can join

Adults 18 to 75, female only, with HR+/HER2- Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Our center plans to conduct a prospective, single-arm exploratory clinical study to evaluate the efficacy and safety of neoadjuvant chemotherapy combined with Anlotinib and Benmelstobart in the treatment of HR+/HER2- breast cancer. The aim is to further explore the treatment strategy of chemotherapy de-escalation for patients with HR+/HER2- breast cancer, provide more treatment options for breast cancer patients, and offer a potential theoretical basis for the precision treatment of breast cancer.The primary study objective is to evaluate the pathologic complete response（PCR）and RCB0-1 ratio of neodjuvant treatment of HR+/HER2- breast cancer.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Benmelstobart+anlotinib: an emerging therapeutic option in the targeted-immunotherapy era.
Cheng P, Gu H, Chen Q, Zhao G, et al · · 2026 · PMID 42052493 · DOI 10.3389/fonc.2026.1748214

Verify or expand the search:

Other recruiting trials for HR+/HER2- Breast Cancer

Currently open trials in the same condition.

NCT07581834 — Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multic · Phase 2 · recruiting
NCT06967103 — QL1706 for the Neoadjuvant Treatment of HR+/HER2- Breast Cancer · Phase 2 · recruiting
NCT06860529 — Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer · Phase 2 · recruiting
NCT06977893 — Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Paralle · Phase 3 · recruiting
NCT07130643 — Efficacy and Safety of CDK4/6 Inhibitors Combined With Endocrine Therapy in HR+/HER2- Neoadjuvant Therapy for Early Brea · Phase 2 · active not recruiting

Other First Affiliated Hospital of Zhejiang University trials

Trials by the same sponsor.

NCT07537192 — Inulin-Spirulina Co-intervention for Insomnia Disorder · NA · not yet recruiting
NCT07510867 — 18F-FAPI PET/CT and MRI in Gastric Cancer · not yet recruiting
NCT07589647 — Research on the Efficacy and Safety of Targeted Suprachiasmatic Nucleus Electrical Stimulation for Improving Metabolic D · NA · recruiting
NCT07525765 — AI-assisted Decision-making of Reoperation for Postoperative Bleeding of Gastric Cancer · recruiting
NCT07468162 — Characteristic Electroencephalogram of General Anesthesia · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06874933 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by First Affiliated Hospital of Zhejiang University
Last refreshed: 12 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06874933.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing